Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, Monde Muyoyeta, Allan C deCamp, Zonglin He, Nicole Grunenberg, Faatima Laher Omar, Kelly E Seaton, Laura Polakowski, Amanda S Woodward Davis, Lucas Maganga, Lindsey R Baden, Kenneth Mayer, Spyros Kalams, Michael Keefer, Srilatha Edupuganti, Benigno Rodriguez, Ian Frank, Hyman Scott, Lynda Stranix-Chibanda, Sanjay Gurunathan, Marguerite Koutsoukos, Olivier Van Der Meeren, Carlos A DiazGranados, Carmen Paez, Erica Andersen-Nissen, James Kublin, Lawrence Corey, Guido Ferrari, Georgia Tomaras, M Juliana McElrath
BACKGROUND: HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled HIV vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent subtype C gp120 Env protein at two dose levels in healthy HIV-uninfected adults. Trial registration URL https://clinicaltrials.gov/ct2/show/NCT03122223 and registration number NCT03122223. METHODS: Participants received ALVAC-HIV (vCP2438) alone or placebo at months 0 and 1...
October 5, 2023: Journal of Infectious Diseases